Technical Analysis for ALLR - Allarity Therapeutics, Inc.

Grade Last Price % Change Price Change
F 0.08 -31.95% -0.04
ALLR closed down 31.95 percent on Friday, March 24, 2023, on 4.22 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Volume Surge Other 0.00%
Calm After Storm Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction -31.95%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 12 hours ago
Fell Below Lower Bollinger Band about 12 hours ago
Gapped Down (Full) about 13 hours ago
2x Volume Pace about 13 hours ago
1.5x Volume Pace about 13 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Allarity Therapeutics, Inc. Description

Allarity Therapeutics A/S develops various therapeutic candidates for the treatment of cancer using drug-specific companion diagnostics (cDx) generated by its drug response predictor technology. Its lead therapeutic candidate is dovitinib, a second-generation pan-tyrosine kinase inhibitor with the ability to inhibit numerous classes of tumor-driving tyrosine kinases, including FGFR, VEGFR, PDGFR, c-Kit, Flt-3, and CSF-1. The company's therapeutic candidates also include stenoparib, selective inhibitor of the key DNA damage repair enzyme poly-ADP-ribose polymerase; and IXEMPRA, a selective microtubule inhibitor that interferes with cancer cell division through mitotic arrest. It also developing other therapeutic candidates comprising LiPlaCis, a targeted liposomal formulation of Cisplatin; 2X-111, a targeted liposomal formulation of Doxorubicin; and Irofulven, a DNA damaging agent. The company was founded in 2004 and is headquartered in Horsholm, Denmark.


Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Health Sciences Drugs Treatment Of Cancer Enzymes Protein Kinase Inhibitor Tyrosine Kinase Doxorubicin Liposome

Is ALLR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.326
52 Week Low 0.072
Average Volume 4,656,531
200-Day Moving Average 0.76
50-Day Moving Average 0.19
20-Day Moving Average 0.15
10-Day Moving Average 0.12
Average True Range 0.03
RSI 27.54
ADX 24.31
+DI 32.58
-DI 25.50
Chandelier Exit (Long, 3 ATRs) 0.14
Chandelier Exit (Short, 3 ATRs) 0.16
Upper Bollinger Bands 0.22
Lower Bollinger Band 0.08
Percent B (%b) -0.01
BandWidth 95.54
MACD Line -0.03
MACD Signal Line -0.02
MACD Histogram -0.0042
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.11
Resistance 3 (R3) 0.12 0.11 0.11
Resistance 2 (R2) 0.11 0.10 0.11 0.11
Resistance 1 (R1) 0.09 0.09 0.09 0.09 0.10
Pivot Point 0.08 0.08 0.08 0.08 0.08
Support 1 (S1) 0.07 0.07 0.06 0.06 0.05
Support 2 (S2) 0.06 0.07 0.06 0.05
Support 3 (S3) 0.04 0.06 0.05
Support 4 (S4) 0.04